AJ Lanigan: Yes. In Fact, pharma companies are building massive dollars with solutions like Keytruda and Opdivo that deal with PD-one and PD-L1. Listed here’s the super awesome part: think about checkpoints as targeted traffic alerts. You don’t want an immune process that’s working wild just like a freight teach waiting for link from Social Bookmarking